Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen

Acta Pharmacologica Sinica

Volumn 30, Issue 1, 2009, Pages 42-53

  Cheng, Heng Hui ^a   Hu, Xiao Jing ^a   Ruan, Qiu Rong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

All trans retinoic acid; Athero sclerosis; Cytochrome P450 aromatase; Dehydroepiandrosterone; MCP 1; Transfection; VCAM 1

Indexed keywords

AROMATASE; ESTROGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PRASTERONE; RETINOIC ACID; VASCULAR CELL ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; GENE EXPRESSION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; TRANSIENT TRANSFECTION; ANIMAL; ARTERY; BLOOD; CYTOLOGY; DIET; GENETICS; HISTOLOGY; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOKINE CCL2; DEHYDROEPIANDROSTERONE; DIET; ESTROGENS; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RABBITS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 64849088458     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.2     Document Type: Article

References (41)

1. Parker CR. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids 1999; 64: 640-7.
2. Zdrojewicz Z, Ciszko B. Dehydroepiandrosterone (DHEA)-structure, clinical importance and the role in human body. Postepy Hig Med Dosw 2001; 55: 835-54.
3. Williams JR. The effects of dehydroepiandrosterone on carcino-genesis, obesity, the immune system, and aging. Lipids 2000; 35: 325-31.
4. PorŠovÁ-dutoit I, ŠulcovÁ J, StÁrka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 2000; 49 (Suppl 1): S43-S56.
5. Fredrick CWW, Arnold VE. Androgens and coronary artery disease. Endocrine Rev 2003; 24: 183-217.
6. Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. Fertil Steril 2002; 77: S26-S33.
7. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002; 77: S34-S41.
8. Hayashi T, Muto E, Kano H, Asai Y, Takur NK, et al. Dehydro-epiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000; 20: 782-92.
9. Yoneyama A, Kamiya Y, Kawaguchi M, Fujinami T. Effects of dehydroepiandrosterone on proliferation of human aortic muscle cells. Life Sci 1997; 60: 833-8.
10. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
11. Takahashi M, Ikeda U, Masuyama J, Kitagawa S, Kasahara T, Saito M, et al. Involvement of adhesion molecules in human monocyte adhesion to and transmigration through endothelial cells in vitro. Atherosclerosis 1994; 108: 73-81.
12. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocyte-macrophage recruitment: a special role for monocyte chemotactic protein-1. Circulation 1992; 86 (Suppl III): III-20-III-25.
13. Kuijpers T W, Harlan JM. Monocyte-endothelial interactions: insights and questions. J Lab Clin Med 1993; 122: 641-51.
14. Iivama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
15. Walker LN, Reidy MA, Bowyer DE. Morphology and cell kinetics of fatty streak lesion formation in the hypercholesterolemic rabbit. Am J Pathol 1986; 125: 450-9.
16. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 1993; 92: 471-8.
17. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-7.
18. Freshney RI. Culture of Animal Cells: A Manual of Basic Technique. New York: Alan R. Liss, Inc; 1987.
19. Rao MS, Ide RE, Subbarao V, Reddy AJ. Dehydroepiandrosterone induced peroxisome proliferation in the rat: evaluation of sex differences. Proc Soc Exp Biol Med 1994; 20: 186-90.
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
21. Brown AJ. Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 2000; 11: 667-9.
22. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991; 14(2 Suppl 1): 11-6.
23. Barret-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 1995; 774: 259-70.
24. López-Marure R, Huesca-Gómez C, Ibarra-Sánchez Mde J, Zentella A, Pérez-Méndez O. Dehydroepiandrosterone delays LDL oxidation in vitro and attenuates several oxLDL-induced inflammatory responses in endothelial cells. Inflamm Allergy Drug Targets 2007; 6: 174-82.
25. Vatalas IA, Diony-Asteriou A. Adrenal C19 steroids and lipoprotein levels in healthy men. Nutr Metab Cardiovasc Dis 2001; 1: 388-93.
26. Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in pro-portion to the severity. J Clin Endocrinol Metab 2000; 85: 1834- 40.
27. Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M, et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005; 50: 305-11.
28. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 2001; 86: 1968-72.
29. Hayashi T, Esaki T, Muto E, Kano H, Asai Y, Thakur NK, et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: The possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000; 20: 782-92.
30. Bouraima H, Hanoux V, Mitre H. Expression of the rabbit cyto-chrome P450 aromatase encoding gene uses alternative tissuespecifc promoters. Eur J Biochem 2001; 268: 4506-12.
31. Shozu M, Zhao Y, Bulun SE, Simpson ER. Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. Endocrinology 1998; 139: 1610-7.
32. Chen J, He B, Zheng D, Zhang S, Liu J, Zhu S. All-trans retinoic acid reduces intimal thickening after balloon angioplasty in atherosclerotic rabbits. Chin Med J (Engl) 1999; 112: 121-3.
33. Maiti S, Chen X, Chen G. All-trans retinoic acid induction of sulfotransferases. Basic Clin Pharmacol Toxicol 2005; 96: 44-53.
34. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma 386 seminars in reproductive medicine/volume 22, number 4 2004 membrane receptor coupled to Galpha(i2,3). J Biol Chem 2002; 277: 21 379-88.
35. Furutama D, Fukui R, Amakawa M, Ohsawa N. Inhibition of migra tion and proliferation of vascular smooth muscle cells by dehydro epiandrosterone sulfate. Biochim Biophys Acta 1998; 1406: 107-14.
36. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003; 144: 3449-55.
37. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002; 87: 176-81.
38. Zapata E, Ventura JL, De la Cruz K, Rodriguez E, Damián P, Massó F, et al. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogenreceptor independent. FEBS J 2005; 272: 1343-53.
39. Daynes R, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993; 150: 5219-30.
40. Spencer NF, Norton SD, Harrison LL, Li GZ, Daynes R. Dysre-gulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp Gerontol 1996; 31: 393-408.
41. Gutiérrez G, Zapata E, Montiel A, Reyes E, Montañ;o LF, et al. Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis 2007; 190: 90-9.